Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study

Imagem de Miniatura
Arquivos
art_FERNANDEZ_Conditional_recurrencefree_survival_of_clinical_complete_responders_managed_2021.PDF (1.14 MB)
Citações na Scopus
118
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
FERNANDEZ, Laura M.
JULIAO, Guilherme P. Sao
FIGUEIREDO, Nuno L.
BEETS, Geerard L.
VALK, Maxime J. M. van der
BAHADOER, Renu R.
HILLING, Denise E.
KRANENBARG, Elma Meershoek-Klein
ROODVOETS, Annet G. H.
RENEHAN, Andrew G.
Citação
LANCET ONCOLOGY, v.22, n.1, p.43-50, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. It is unclear for how long these patients should be followed up. To address this issue, we did conditional survival modelling using the International Watch & Wait Database (IWWD), which is a large-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watch-and-wait strategy. Methods We did a retrospective, multicentre registry study using a dataset from the IWWD, which includes data from 47 clinics across 15 countries. We selected patients (aged >= 18 years) with rectal cancer who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently managed by a watch-and-wait strategy between Nov 25,1991, and Dec 31,2015. Patients who had not achieved a clinical complete response or who had undergone any surgical procedure were excluded. The criteria used for defining a clinical complete response and the specific surveillance strategies were at the discretion of each participating centre. We used conditional survival modelling to estimate the probability of patients remaining free of local regrowth or distant metastasis for an additional 2 years after sustaining a clinical complete response or being distant metastasis-free for 1,3, and 5 years from the date of the decision to commence watch and wait. The primary outcomes were conditional local regrowth-free survival at 3 years, and conditional distant metastasis-free survival at 5 years. Findings We identified 793 patients in the IWWD with clinical complete response who had been managed by a watch-and-wait strategy. Median follow-up was 55.2 months (IQR 36.0-75.6). The probability of remaining free from local regrowth for an additional 2 years if a patient had a sustained clinical complete response for 1 year was 88.1% (95% CI 85.8-90.9), for 3 years was 97.3% (95.2-98.6), and for 5 years was 98.6% (97.6-100.0). The probably of remaining free from distant metastasis for a further 2 years in patients who had a clinical complete response without distant metastasis for 1 year was 93.8% (92.3-95.9), for 3 years was 97.8% (96.6-99.3), and for 5 years was 96.6% (94.0-98.9). Interpretation These results suggest that the intensity of active surveillance in patients with rectal cancer managed by a watch-and-wait approach could be reduced if they achieve and maintain a clinical complete response within the first 3 years of starting this approach.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/39856
Referências
  1. Beets GL, 2015, EJSO-EUR J SURG ONC, V41, P1562, DOI 10.1016/j.ejso.2015.09.008
  2. Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061
  3. Brown G, 2006, BRIT MED J, V333, P779, DOI 10.1136/bmj.38937.646400.55
  4. Chadi SA, 2018, LANCET GASTROENTEROL, V3, P825, DOI 10.1016/S2468-1253(18)30301-7
  5. Cucchetti A, 2012, CLIN CANCER RES, V18, P4397, DOI 10.1158/1078-0432.CCR-11-2663
  6. Dattani M, 2018, ANN SURG, V268, P955, DOI 10.1097/SLA.0000000000002761
  7. Glynne-Jones R, 2018, ANN ONCOL, V29, P263, DOI 10.1093/annonc/mdy161
  8. Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32
  9. Habr-Gama A, 2006, J GASTROINTEST SURG, V10, P1319, DOI 10.1016/j.gassur.2006.09.005
  10. Habr-Gama A, 2017, DIS COLON RECTUM, V60, P586, DOI 10.1097/DCR.0000000000000830
  11. Habr-Gama A, 2014, INT J RADIAT ONCOL, V88, P822, DOI 10.1016/j.ijrobp.2013.12.012
  12. Karagkounis G, 2019, DIS COLON RECTUM, V62, P33, DOI 10.1097/DCR.0000000000001239
  13. Myint AS, 2018, INT J RADIAT ONCOL, V100, P565, DOI 10.1016/j.ijrobp.2017.10.022
  14. Renehan AG, 2016, LANCET ONCOL, V17, P174, DOI 10.1016/S1470-2045(15)00467-2
  15. Sao Juliao GP, 2020, ANN SURG, V272, P138, DOI 10.1097/SLA.0000000000003286
  16. Sekhar H, 2017, LANCET ONCOL, V18, P1348, DOI 10.1016/S1470-2045(17)30456-4
  17. Smith JJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1632-z
  18. van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X
  19. Zabor EC, 2013, CANCER-AM CANCER SOC, V119, P3589, DOI 10.1002/cncr.28273

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - ODS/03